Results 251 to 260 of about 95,219 (308)
Some of the next articles are maybe not open access.
Neurologic complications of hematologic neoplasms
Neurologic Clinics, 2003The new WHO classification of hematopoietic and lymphatic neoplasms was devised to offer pathologists, oncologists, and geneticists a system of classification based on histopathologic, clinical, and genetic features. From the neurologic standpoint, it offers an opportunity to consolidate the complications produced by leukemias, lymphomas, and plasma ...
Lawrence, Recht, Maciej, Mrugala
openaire +2 more sources
Rheumatologic Manifestations of Hematologic Neoplasms
Current Rheumatology Reviews, 2017The rheumatologic manifestations of hematologic neoplasms are a collection of diverse syndromes. This review aims to describe the most common syndromes in the context of potential mechanisms of pathogenesis.We undertook a structured search of the available peer-reviewed literature describing paraneoplastic phenomena associated with hematologic ...
A, Wang, C M, Brunet, A M, Zeidan
openaire +2 more sources
Immunologic Aspects of the Hematologic Neoplasms
Postgraduate Medicine, 1973Understanding the pathogenesis and pathophysiology of the hematologic malignancies now requires knowledge of their immunology. Many of these tumors appear to arise from the immune cells themselves (B or T cell tumors); most have associated disturbances in immune cell function.
S E, Jones, B G, Durie, S E, Salmon
openaire +2 more sources
Flow cytometric immunophenotyping for hematologic neoplasms
Blood, 2008AbstractFlow cytometric immunophenotyping remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded range of antibodies and fluorochromes that have improved our ability to identify different ...
Fiona E, Craig, Kenneth A, Foon
openaire +2 more sources
BRAF — A new player in hematological neoplasms
Blood Cells, Molecules, and Diseases, 2014BRAF oncogenic kinase has become a target for specific therapy in oncology. Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib.
Marcin M. Machnicki, Tomasz Stoklosa
openaire +2 more sources
[Hematologic changes in renal neoplasms].
Minerva medica, 1984The main haematological parameters, particularly haemoglobin concentration and the numbers of leukocytes and platelets, were studied in 146 kidney tumour patients. Only 119 of the subjects studied later underwent nephrectomy. In 66 patients the tumours were limited to within the renal capsule (group I) while in 39 other subjects the tumours had gone ...
PICCININI, Lino +4 more
openaire +2 more sources
[Hypocholesterolemia in hematologic neoplasms].
Sangre, 1997To evaluate the cholesterol metabolism in oncohaematologic patients and its inclusion as a biochemical marker as well as other parameters in the diagnostic period (leukocytes, deshidrogenase lactate, erithrosedimentation, haptoglobine). Many different epidemiological studies discuss the relation between the high risk for cancer mortality and low blood ...
M, Aixalá +2 more
openaire +1 more source
Cytogenetics of Hematologic Neoplasms
2005Cancer is a genetic disease that could develop either from a predisposing mutation followed by acquired somatic mutations or from an accumulation of somatic mutations that develop into a cancer phenotype. Many different types of DNA alteration have been reported in cancer, with some of the recognized forms being as follows: Subtle DNA or RNA ...
openaire +1 more source
Cellular Origins of Hematologic Neoplasms
New England Journal of Medicine, 1990The entire hematopoietic system in all its complexity arises from a small number of stem cells that not only differentiate but also replenish the bone marrow by a process of self-renewal. These stem cells supply the marrow with committed progenitor cells that become the main hematopoietic cell types.
Rachel J. Buchsbaum, Robert S. Schwartz
openaire +1 more source
Hematologic neoplasms: Dendritic cells vaccines in motion
Clinical Immunology, 2017Dendritic cells (DCs) are bone-marrow-derived immune cells accounted for a key role in cancer vaccination as potent antigen-presenting cells within the immune system. Cancer microenvironment can modulate DCs maturation resulting in their accumulation into functional states associated with a reduced antitumor immune response.
Domenico, Galati, Serena, Zanotta
openaire +2 more sources